Categories
Featured Exclusive
In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In this interview with i3 Health, Samuel L. Washington III, MD, MAS, Assistant Professor of Urology at the University of California San Francisco and the study's lead author, discusses the significance ...
Top Oncology Stories
Wednesday, January 20, 2021
In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In...
Tuesday, January 19, 2021
The FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) for the treatment of adult patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-posi...
Monday, January 18, 2021
The FDA has granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro®, Janssen Biotech, Inc.) in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the t...
Friday, January 15, 2021
Crizotinib (Xalkori®, Pfizer) is now FDA approved for the treatment of pediatric patients age one year and older and young adult patients with relapsed/refractory systemic ALK-positive anaplastic larg...
Thursday, January 14, 2021
Standard treatment for metastatic colorectal cancer (mCRC) typically involves antiangiogenic therapies, which block angiogenesis, the formation of new blood vessels, thereby starving cancer cells. Anl...
Wednesday, January 13, 2021
In patients with locally advanced gastric cancer, perioperative chemotherapy consisting of TAS-118 (S-1 and leucovorin) plus oxaliplatin shows promise with a tolerable safety profile, according to saf...
Most Popular
Expert Perspectives
In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In this interview with i3 Health, Samuel L. Washingt...
Relugolix (OrgovyxTM, Myovant Sciences) was recently FDA approved as the first oral hormone therapy for patients with advanced prostate cancer. In this interview, Neal Shore, MD, FACS, Medical Director of the Carolina Urologic Research Center and lea...
Recently, the FDA approved osimertinib (Tagrisso®, AstraZeneca) as the first adjuvant therapy for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In this intervi...
In a study published this past week in JAMA Network Open, Eugene Cone, MD, and colleagues found that a longer time to treatment initiation negatively impacts survival in patients with breast, prostate, colon, and lung cancers, a finding that is parti...
Recently, the FDA approved naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow. In this interview, Jaume Mora, MD, PhD, Scien...
Original Research
Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline knowledge gaps regardi...
At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to r...
Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline k...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health ...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symp...
